These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 34524023

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
    Stone MP, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, Kaufman FR.
    Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J, Pöhlmann J, de Portu S, Smith-Palmer J, Roze S.
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System.
    Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM.
    Diabetes Care; 2019 Dec; 42(12):2190-2196. PubMed ID: 31548247
    [Abstract] [Full Text] [Related]

  • 9. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®.
    Grosman B, Wu D, Parikh N, Roy A, Voskanyan G, Kurtz N, Sturis J, Cohen O, Ekelund M, Vigersky R.
    Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Real-World Patient Experience of Long-Term Hybrid Closed-Loop Insulin Pump Use.
    Wang LR, Malcolm J, Arnaout A, Humphrey-Murto S, LaDonna KA.
    Can J Diabetes; 2021 Dec; 45(8):750-756.e3. PubMed ID: 33958309
    [Abstract] [Full Text] [Related]

  • 18. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
    Arunachalum S, Velado K, Vigersky RA, Cordero TL.
    J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
    [Abstract] [Full Text] [Related]

  • 19. Fast-Acting Insulin Aspart Use with the MiniMedTM 670G System.
    Hsu L, Buckingham B, Basina M, Ekhlaspour L, von Eyben R, Wang J, Lal RA.
    Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.